{
    "xml": "<topic id=\"PHP1600\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/tranexamic-acid\" basename=\"tranexamic-acid\" title=\"TRANEXAMIC ACID\">\n<title>TRANEXAMIC ACID</title>\n<body>\n<data name=\"vtmid\">109006003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_463346206\" title=\"Antifibrinolytics\">Antifibrinolytics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP35213\" outputclass=\"indicationsAndDose\" rev=\"1.37\" parent=\"/drugs/tranexamic-acid\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Inhibition of fibrinolysis (local)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;1.5&#8239;g 2&#8211;3 times a day, alternatively 15&#8211;25&#8239;mg/kg 2&#8211;3 times a day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">Initially by slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8211;1&#8239;g 2&#8211;3 times a day, to be administered at a rate not exceeding 100&#8239;mg/minute, dose may be followed by continuous infusion; (by continuous intravenous infusion) 25&#8211;50&#8239;mg/kg, dose to be given over 24 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Menorrhagia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g 3 times a day for up to 4 days, to be initiated when menstruation has started; maximum 4&#8239;g per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hereditary angioedema</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;1.5&#8239;g 2&#8211;3 times a day, for short-term prophylaxis of hereditary angioedema, tranexamic acid is started several days before planned procedures which may trigger an acute attack of hereditary angioedema (e.g. dental work) and continued for 2&#8211;5 days afterwards.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Epistaxis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g 3 times a day for 7 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">General fibrinolysis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g every 6&#8211;8&#8239;hours, alternatively 15&#8239;mg/kg every 6&#8211;8&#8239;hours, dose to be given at a rate not exceeding 100mg/minute.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61842\" outputclass=\"unlicensedUse\" rev=\"1.12\" parent=\"/drugs/tranexamic-acid\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Use of tranexamic acid by continuous intravenous infusion for treatment of local fibrinolysis is an unlicensed route of administration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35508\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/tranexamic-acid\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of fibrinolytic system with severe bleeding)</ph>; <ph outputclass=\"contraindication\">history of convulsions</ph>; <ph outputclass=\"contraindication\">thromboembolic disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35604\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/tranexamic-acid\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Irregular menstrual bleeding (establish cause before initiating therapy)</ph>; <ph outputclass=\"caution\">massive haematuria (avoid if risk of ureteric obstruction)</ph>; <ph outputclass=\"caution\">patients receiving oral contraceptives (increased risk of thrombosis)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Menorrhagia</p>\n<p>Before initiating treatment for menorrhagia, exclude structural or histological causes or fibroids causing distortion of uterine cavity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62117\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/tranexamic-acid\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Diarrhoea (reduce dose)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dermatitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Impairment of colour vision (discontinue)</ph>; <ph outputclass=\"sideEffect\">thromboembolic events</ph>; <ph outputclass=\"sideEffect\">visual disturbances (discontinue)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Convulsions (usually with high doses)</ph>; <ph outputclass=\"sideEffect\">hypotension (on rapid intravenous injection)</ph>; <ph outputclass=\"sideEffect\">malaise (on rapid intravenous injection)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34853\" outputclass=\"pregnancy\" parent=\"/drugs/tranexamic-acid\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No evidence of teratogenicity in <i>animal </i> studies; manufacturer advises use only if potential benefit outweighs risk&#8212;crosses the placenta.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35667\" outputclass=\"breastFeeding\" parent=\"/drugs/tranexamic-acid\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Small amount present in milk&#8212;antifibrinolytic effect in infant unlikely.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62321\" outputclass=\"renalImpairment\" parent=\"/drugs/tranexamic-acid\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose&#8212;consult product literature for details.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61798\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tranexamic-acid\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Regular liver function tests in long-term treatment of hereditary angiodema.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35901\" outputclass=\"directionsForAdministration\" rev=\"1.15\" parent=\"/drugs/tranexamic-acid\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Cyklokapron</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium chloride 0.9%.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1600-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tranexamic-acid\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, mouthwash</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76904\" title=\"Tablet\" namespace=\"/drugs/tranexamic-acid/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76911\" title=\"Solution for injection\" namespace=\"/drugs/tranexamic-acid/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"2\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78111\" namespace=\"/treatment-summaries/antihistamines-allergen-immunotherapy-and-allergic-emergencies\" title=\"Antihistamines, allergen immunotherapy and allergic emergencies\" count=\"2\" rel=\"backlink\">Antihistamines, allergen immunotherapy and allergic emergencies</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78133\" namespace=\"/treatment-summaries/antifibrinolytic-drugs-and-haemostatics\" title=\"Antifibrinolytic drugs and haemostatics\" count=\"2\" rel=\"backlink\">Antifibrinolytic drugs and haemostatics</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78400\" namespace=\"/treatment-summaries/sex-hormones\" title=\"Sex hormones\" count=\"1\" rel=\"backlink\">Sex hormones</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78556\" namespace=\"/treatment-summaries/platelet-disorders\" title=\"Platelet disorders\" count=\"1\" rel=\"backlink\">Platelet disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76904\" namespace=\"/drugs/tranexamic-acid/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76911\" namespace=\"/drugs/tranexamic-acid/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1600",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/tranexamic-acid",
    "basename": "tranexamic-acid",
    "title": "TRANEXAMIC ACID",
    "vtmid": "109006003",
    "drugClassification": [
        "Antifibrinolytics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Inhibition of fibrinolysis (local)",
                        "html": "Inhibition of fibrinolysis (local)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially slow intravenous injection"
                    ],
                    "textContent": "Initially by slow intravenous injection",
                    "html": "Initially by slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;1.5 g 2&#8211;3 times a day, alternatively 15&#8211;25 mg/kg 2&#8211;3 times a day.",
                        "html": "<p>1&#8211;1.5&#8239;g 2&#8211;3 times a day, alternatively 15&#8211;25&#8239;mg/kg 2&#8211;3 times a day.</p>"
                    },
                    {
                        "textContent": "0.5&#8211;1 g 2&#8211;3 times a day, to be administered at a rate not exceeding 100 mg/minute, dose may be followed by continuous infusion; (by continuous intravenous infusion) 25&#8211;50 mg/kg, dose to be given over 24 hours.",
                        "html": "<p>0.5&#8211;1&#8239;g 2&#8211;3 times a day, to be administered at a rate not exceeding 100&#8239;mg/minute, dose may be followed by continuous infusion; (by continuous intravenous infusion) 25&#8211;50&#8239;mg/kg, dose to be given over 24 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Menorrhagia",
                        "html": "Menorrhagia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1 g 3 times a day for up to 4 days, to be initiated when menstruation has started; maximum 4 g per day.",
                        "html": "<p>1&#8239;g 3 times a day for up to 4 days, to be initiated when menstruation has started; maximum 4&#8239;g per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Hereditary angioedema",
                        "html": "Hereditary angioedema"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;1.5 g 2&#8211;3 times a day, for short-term prophylaxis of hereditary angioedema, tranexamic acid is started several days before planned procedures which may trigger an acute attack of hereditary angioedema (e.g. dental work) and continued for 2&#8211;5 days afterwards.",
                        "html": "<p>1&#8211;1.5&#8239;g 2&#8211;3 times a day, for short-term prophylaxis of hereditary angioedema, tranexamic acid is started several days before planned procedures which may trigger an acute attack of hereditary angioedema (e.g. dental work) and continued for 2&#8211;5 days afterwards.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Epistaxis",
                        "html": "Epistaxis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1 g 3 times a day for 7 days.",
                        "html": "<p>1&#8239;g 3 times a day for 7 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "General fibrinolysis",
                        "html": "General fibrinolysis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection"
                    ],
                    "textContent": "By slow intravenous injection",
                    "html": "By slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1 g every 6&#8211;8 hours, alternatively 15 mg/kg every 6&#8211;8 hours, dose to be given at a rate not exceeding 100mg/minute.",
                        "html": "<p>1&#8239;g every 6&#8211;8&#8239;hours, alternatively 15&#8239;mg/kg every 6&#8211;8&#8239;hours, dose to be given at a rate not exceeding 100mg/minute.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Use of tranexamic acid by continuous intravenous infusion for treatment of local fibrinolysis is an unlicensed route of administration.",
                "html": "<p>Use of tranexamic acid by continuous intravenous infusion for treatment of local fibrinolysis is an unlicensed route of administration.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of fibrinolytic system with severe bleeding)",
                "html": "Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of fibrinolytic system with severe bleeding)"
            },
            {
                "type": "contraindications",
                "textContent": "history of convulsions",
                "html": "history of convulsions"
            },
            {
                "type": "contraindications",
                "textContent": "thromboembolic disease",
                "html": "thromboembolic disease"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Irregular menstrual bleeding (establish cause before initiating therapy)",
                "html": "Irregular menstrual bleeding (establish cause before initiating therapy)"
            },
            {
                "type": "cautions",
                "textContent": "massive haematuria (avoid if risk of ureteric obstruction)",
                "html": "massive haematuria (avoid if risk of ureteric obstruction)"
            },
            {
                "type": "cautions",
                "textContent": "patients receiving oral contraceptives (increased risk of thrombosis)",
                "html": "patients receiving oral contraceptives (increased risk of thrombosis)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Menorrhagia",
                "textContent": "Before initiating treatment for menorrhagia, exclude structural or histological causes or fibroids causing distortion of uterine cavity.",
                "html": "<p>Before initiating treatment for menorrhagia, exclude structural or histological causes or fibroids causing distortion of uterine cavity.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Diarrhoea (reduce dose)",
                        "html": "Diarrhoea (reduce dose)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dermatitis",
                        "html": "Dermatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Impairment of colour vision (discontinue)",
                        "html": "Impairment of colour vision (discontinue)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "thromboembolic events",
                        "html": "thromboembolic events",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "visual disturbances (discontinue)",
                        "html": "visual disturbances (discontinue)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Convulsions (usually with high doses)",
                        "html": "Convulsions (usually with high doses)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension (on rapid intravenous injection)",
                        "html": "hypotension (on rapid intravenous injection)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "malaise (on rapid intravenous injection)",
                        "html": "malaise (on rapid intravenous injection)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No evidence of teratogenicity in animal studies; manufacturer advises use only if potential benefit outweighs risk&#8212;crosses the placenta.",
                "html": "<p>No evidence of teratogenicity in <i>animal </i> studies; manufacturer advises use only if potential benefit outweighs risk&#8212;crosses the placenta.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Small amount present in milk&#8212;antifibrinolytic effect in infant unlikely.",
                "html": "<p>Small amount present in milk&#8212;antifibrinolytic effect in infant unlikely.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose&#8212;consult product literature for details.",
                "html": "<p>Reduce dose&#8212;consult product literature for details.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Regular liver function tests in long-term treatment of hereditary angiodema.",
                "html": "<p>Regular liver function tests in long-term treatment of hereditary angiodema.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Cyklokapron ), give continuously in Glucose 5% or Sodium chloride 0.9%.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Cyklokapron</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium chloride 0.9%.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "mouthwash"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76904",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76911",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78111",
                "label": "Antihistamines, allergen immunotherapy and allergic emergencies",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78133",
                "label": "Antifibrinolytic drugs and haemostatics",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78400",
                "label": "Sex hormones",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78556",
                "label": "Platelet disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76904",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76911",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}